Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 545

1.

H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans.

Khurana S, Wu J, Verma N, Verma S, Raghunandan R, Manischewitz J, King LR, Kpamegan E, Pincus S, Smith G, Glenn G, Golding H.

J Virol. 2011 Nov;85(21):10945-54. doi: 10.1128/JVI.05406-11. Epub 2011 Aug 24.

2.

Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle.

Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, Cole KS, Kumar NM, Pushko P, Smith G, Tumpey TM, Ross TM.

PLoS One. 2008 Jan 30;3(1):e1501. doi: 10.1371/journal.pone.0001501.

3.

H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.

Mahmood K, Bright RA, Mytle N, Carter DM, Crevar CJ, Achenbach JE, Heaton PM, Tumpey TM, Ross TM.

Vaccine. 2008 Oct 3;26(42):5393-9. doi: 10.1016/j.vaccine.2008.07.084. Epub 2008 Aug 14.

PMID:
18706956
4.

Heterosubtypic antibody response elicited with seasonal influenza vaccine correlates partial protection against highly pathogenic H5N1 virus.

Ding H, Tsai C, Zhou F, Buchy P, Deubel V, Zhou P.

PLoS One. 2011 Mar 25;6(3):e17821. doi: 10.1371/journal.pone.0017821.

5.

Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.

Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, Rock MT, Edwards KM, Del Giudice G, Rappuoli R, Golding H.

Sci Transl Med. 2010 Jan 20;2(15):15ra5. doi: 10.1126/scitranslmed.3000624.

6.

Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.

Liu WC, Lin CY, Tsou YT, Jan JT, Wu SC.

J Virol. 2015 Jul;89(14):7224-34. doi: 10.1128/JVI.00585-15. Epub 2015 May 6.

7.

The antigenic architecture of the hemagglutinin of influenza H5N1 viruses.

Velkov T, Ong C, Baker MA, Kim H, Li J, Nation RL, Huang JX, Cooper MA, Rockman S.

Mol Immunol. 2013 Dec;56(4):705-19. doi: 10.1016/j.molimm.2013.07.010. Epub 2013 Aug 7. Review.

PMID:
23933511
8.

ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans.

Chung KY, Coyle EM, Jani D, King LR, Bhardwaj R, Fries L, Smith G, Glenn G, Golding H, Khurana S.

Vaccine. 2015 Jul 31;33(32):3953-62. doi: 10.1016/j.vaccine.2015.06.047. Epub 2015 Jun 17.

PMID:
26093202
9.

Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets.

Khurana S, Verma S, Verma N, Crevar CJ, Carter DM, Manischewitz J, King LR, Ross TM, Golding H.

J Virol. 2011 Feb;85(3):1246-56. doi: 10.1128/JVI.02107-10. Epub 2010 Nov 17.

10.

Neutralizing antibody but not hemagglutination antibody provides accurate evaluation for protective immune response to H5N1 avian influenza virus in vaccinated rabbits.

Zhu H, Ding X, Chen X, Yao P, Xu F, Xie R, Yang Z, Liang W, Zhang Y, Li Y, Shen J, He P, Guo Z, Su B, Sun S, Zhu Z.

Vaccine. 2011 Jul 26;29(33):5421-3. doi: 10.1016/j.vaccine.2011.05.067. Epub 2011 Jun 7.

PMID:
21645575
11.

Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.

Smith GE, Flyer DC, Raghunandan R, Liu Y, Wei Z, Wu Y, Kpamegan E, Courbron D, Fries LF 3rd, Glenn GM.

Vaccine. 2013 Sep 13;31(40):4305-13. doi: 10.1016/j.vaccine.2013.07.043. Epub 2013 Jul 26.

12.
13.

Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase.

Tsai C, Caillet C, Hu H, Zhou F, Ding H, Zhang G, Zhou B, Wang S, Lu S, Buchy P, Deubel V, Vogel FR, Zhou P.

Vaccine. 2009 Nov 12;27(48):6777-90. doi: 10.1016/j.vaccine.2009.08.056. Epub 2009 Sep 2.

PMID:
19732860
14.

Reverse engineering the antigenic architecture of the haemagglutinin from influenza H5N1 clade 1 and 2.2 viruses with fine epitope mapping using monoclonal antibodies.

Rockman S, Camuglia S, Vandenberg K, Ong C, Baker MA, Nation RL, Li J, Velkov T.

Mol Immunol. 2013 Apr;53(4):435-42. doi: 10.1016/j.molimm.2012.10.001. Epub 2012 Nov 3.

PMID:
23127859
15.

Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.

Jadhao SJ, Lee CW, Sylte M, Suarez DL.

Vaccine. 2009 Oct 19;27(44):6247-60. doi: 10.1016/j.vaccine.2009.07.110. Epub 2009 Aug 15.

PMID:
19686695
16.

A critical HA1 neutralizing domain of H5N1 influenza in an optimal conformation induces strong cross-protection.

Du L, Zhao G, Sun S, Zhang X, Zhou X, Guo Y, Li Y, Zhou Y, Jiang S.

PLoS One. 2013;8(1):e53568. doi: 10.1371/journal.pone.0053568. Epub 2013 Jan 8.

17.

Cocktail of H5N1 COBRA HA vaccines elicit protective antibodies against H5N1 viruses from multiple clades.

Crevar CJ, Carter DM, Lee KY, Ross TM.

Hum Vaccin Immunother. 2015;11(3):572-83. doi: 10.1080/21645515.2015.1012013.

18.

Development of Clade-Specific and Broadly Reactive Live Attenuated Influenza Virus Vaccines against Rapidly Evolving H5 Subtype Viruses.

Boonnak K, Matsuoka Y, Wang W, Suguitan AL Jr, Chen Z, Paskel M, Baz M, Moore I, Jin H, Subbarao K.

J Virol. 2017 Jul 12;91(15). pii: e00547-17. doi: 10.1128/JVI.00547-17. Print 2017 Aug 1.

PMID:
28490598
19.
20.

H5 N-terminal β sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine.

Khurana S, Coyle EM, Verma S, King LR, Manischewitz J, Crevar CJ, Carter DM, Ross TM, Golding H.

Vaccine. 2014 Nov 12;32(48):6421-32. doi: 10.1016/j.vaccine.2014.09.049. Epub 2014 Oct 3.

PMID:
25284811

Supplemental Content

Support Center